top of page
NemaLife YouTube Banner-2.png

NemaLife News

  • Writer's pictureLevi Glover

February 2024 Industry News

How a new recipe can help food win in an Ozempic world

The surge in anti-obesity medications, particularly GLP-1 agonists, has disrupted the food industry, with reports indicating decreased food purchases among medication users. While pharmaceutical companies invest heavily in marketing GLP-1 agonists, concerns arise regarding costs, side effects, and long-term efficacy. With insights on rising concerns, potential solutions, and the promise of food as medicine, it illuminates pathways for innovative food-centric solutions amidst the evolving landscape of health and wellness. Read More. 


Scientists address debates on postbiotic definition with new paper


Despite the 2021 definition by ISAPP, a recent Frontiers in Microbiology paper by ISAPP-affiliated scientists tackles persisting queries. The study emphasizes that purified or processed metabolites devoid of cellular components don't qualify as postbiotics, underlining the importance of precision in definitions to ensure usefulness. This stance prevents an ambiguous scenario where chemically identical preparations, one microbially derived and the other not, may differ in categorization despite equivalent health benefits.  Read More. 


Obesity drugs have another superpower: taming inflammation


The latest anti-obesity drugs, including GLP-1 receptor agonists like Wegovy and Mounjaro, not only effectively treat diabetes and reduce weight but also possess the ability to suppress inflammation in the liver, kidneys, heart, and brain. Recent studies suggest potential applications in treating neurodegenerative diseases like Parkinson's and Alzheimer's, as these drugs demonstrate anti-inflammatory effects, offering hope for more targeted therapies and expanded applications against various inflammatory disorders with minimal side effects.   Read More. 


Caenorhabditis elegans as a Screening Model for Probiotics with Properties against Metabolic Syndrome


Emerging research highlights the pivotal role of gut microbiota in metabolic syndromes like obesity and type 2 diabetes. Probiotics, particularly lactic acid bacteria and Bifidobacterium, show promise in alleviating metabolic disturbances. However, further in vivo studies, particularly utilizing Caenorhabditis elegans, are crucial to unravel the underlying mechanisms and therapeutic potential of probiotics. Read More.


Lactobacillus paracasei HII01 enhances lifespan and promotes neuroprotection in Caenorhabditis elegans

This study explores the potential of probiotics in promoting healthy aging and protecting against Alzheimer's disease. Novel strains were evaluated for their impact on lifespan extension and protection against amyloid toxicity in Caenorhabditis elegans. Lactobacillus paracasei HII01 showed the most promising results, suggesting its potential as a dietary supplement for healthy aging and disease prevention.  Read More.


bottom of page